| AbbVie17 programs in shared conditions | 7 · 3 with both in phase 3Colitis, Ulcerative, Crohn Disease, Dermatitis, Atopic +4 | telisotuzumab adizutecan, ABBV-1480, risankizumab +2 | - AbbVie’s upadacitinib in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT06389136)
- AbbVie’s zumilokibart in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07027527)
- AbbVie’s APG990 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07027527)
|
| Innovent Biologics, Inc.5 programs in shared conditions | 2 · 1 with both in phase 3Dermatitis, Atopic, Carcinoma, Non-Small-Cell Lung | IBI3027 | - Innovent Biologics, Inc.’s IBI356 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07330934)
- Innovent Biologics, Inc.’s IBI3027 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07754786)
- Innovent Biologics, Inc.’s IBI3002 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07399067)
|
| Pfizer19 programs in shared conditions | 13 · 4 with both in phase 3Colitis, Ulcerative, Dermatitis, Atopic, Hemophilia A +10 | ibuzatrelvir, remdesivir, sigvotatug vedotin +8 | - Sanofi’s Pneumococcal 21-Valent Conjugate Vaccine vs Pneumococcal 20-Valent Conjugate Vaccine (most trials: Pfizer) (Anemia, Sickle Cell, NCT07247188)
- Pfizer’s tilrekimig vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07783425)
|
| Novartis21 programs in shared conditions | 12 · 2 with both in phase 3Multiple Sclerosis, Purpura, Thrombocytopenic, Idiopathic, Chronic Urticaria +9 | remibrutinib, delpacibart zotadirsen, AOC 1001 +1 | - Novartis’s remibrutinib vs dupilumab (EU rights: Sanofi) (Chronic Urticaria, NCT06868212)
|
| Qilu Pharmaceutical Co., Ltd.10 programs in shared conditions | 9 · 2 with both in phase 3Dermatitis, Atopic, Purpura, Thrombocytopenic, Idiopathic, Carcinoma, Non-Small-Cell Lung +6 | QL2107, QLM3003, QL2108 +2 | - Qilu Pharmaceutical Co., Ltd.’s QL2108 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT06884891)
|